← board
AIM
distress 7/10 · high distress / dilution risk$0.26+2%today-97% from 52w high
Lead: Pancreatic cancer · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$22M
Runway
1.9 yrs
Shares 1y
+438%
Price & events
-79.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.0%
1D
-5.6%
1W
-29.2%
1M
-51.0%
3M
-78.1%
6M
-96.9%
1Y
-99.3%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $3.71M
- Enterprise Value
- $-1.89M
- Volume
- 90.19K
- 52 Week Range
- $0.23 – $8.97
- Total Shares
- 14.56M
- Float Shares
- 12.75M
- Short %
- 7.98%
- % Held by Insiders
- 0.59%
- % Held by Institutions
- 0.75%
- RVOL
- 0.04x
- Beta
- 1.20
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- June, 2026enrollment completesecondaryPhase 2Ampligen (rintatolimod) · Completion of enrollment for the DURIPANC Phase 2 trial.SEC 8-K
- 2026-05-20partnershipEntered into securities purchase agreement with institutional investors for registered direct offering and private placement of warrantsSEC 8-K
- 2025-06-17warning letterNYSE American noncompliance warning for minimum stockholders' equity.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-01Ascendiant CapitalBuy
- 2026-04-10Ascendiant CapitalBuy
- 2025-12-08Ascendiant CapitalBuy
- 2025-10-03Ascendiant CapitalBuy
- 2024-12-10Ascendiant CapitalBuy
- 2024-10-22Maxim GroupBuy
Competitors — Pancreatic cancer
- LLYELI LILLY & Co$1094.4B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- JAZZJazz Pharmaceuticals plc$15.7B · D0
- IBRXImmunityBio, Inc.$7.8B · D5
- TNGXTango Therapeutics, Inc.$4.0B · D5
- MNPRMonopar Therapeutics$687M · D1
- IMRXImmuneering Corp$112M · D3
- RNXTRenovoRx, Inc.$39M · D5
- SLXNSilexion Therapeutics Corp$10M · D6
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
- 2026-07-16Shareholders at AIM ImmunoTech (NYSE: AIM) approve >19.99% issuances and reverse split - Stock Titan
- 2026-07-10AIM Should I Buy - Intellectia AI
- 2026-07-07AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - Yahoo Finance
- 2026-06-29Price to sales forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
- 2026-06-28Enterprise value to revenue forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
- 2026-06-25AIM ImmunoTech Inc. Actuals & Estimates (AMEX:AIM) - TradingView
- 2026-06-25AIM Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.